Abstract

Background: The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear. Patients and Methods: Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery. Results: After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15% on multivariable analysis (hazard ratio 1.15 95% confidence interval 1.04.-1.28, p=0.006). Conclusion: The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.

Original languageEnglish
Pages (from-to)5111-5119
Number of pages9
JournalAnticancer Research
Volume29
Issue number12
Publication statusPublished - Dec 2009

Fingerprint

Vascular Endothelial Growth Factor A
Breast Neoplasms
Serum
Disease-Free Survival
Perioperative Period
Biomarkers
Confidence Intervals

Keywords

  • Breast cancer
  • EGFR
  • HER2
  • Surgery
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{d8b5236975294cfd862d7a63005074e3,
title = "Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer",
abstract = "Background: The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear. Patients and Methods: Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery. Results: After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15{\%} on multivariable analysis (hazard ratio 1.15 95{\%} confidence interval 1.04.-1.28, p=0.006). Conclusion: The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.",
keywords = "Breast cancer, EGFR, HER2, Surgery, VEGF",
author = "Andrea Rocca and Giuseppe Cancello and Vincenzo Bagnardi and Sandri, {Maria Teresa} and Rosalba Torrisi and Laura Zorzino and Giuseppe Viale and Elisabetta Pietri and Paolo Veronesi and Silvia Dellapasqua and Francesco Ferrucci and Alberto Luini and Harriet Johansson and Raffaella Ghisini and Aron Goldhirsch and Marco Colleoni",
year = "2009",
month = "12",
language = "English",
volume = "29",
pages = "5111--5119",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer

AU - Rocca, Andrea

AU - Cancello, Giuseppe

AU - Bagnardi, Vincenzo

AU - Sandri, Maria Teresa

AU - Torrisi, Rosalba

AU - Zorzino, Laura

AU - Viale, Giuseppe

AU - Pietri, Elisabetta

AU - Veronesi, Paolo

AU - Dellapasqua, Silvia

AU - Ferrucci, Francesco

AU - Luini, Alberto

AU - Johansson, Harriet

AU - Ghisini, Raffaella

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2009/12

Y1 - 2009/12

N2 - Background: The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear. Patients and Methods: Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery. Results: After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15% on multivariable analysis (hazard ratio 1.15 95% confidence interval 1.04.-1.28, p=0.006). Conclusion: The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.

AB - Background: The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear. Patients and Methods: Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery. Results: After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15% on multivariable analysis (hazard ratio 1.15 95% confidence interval 1.04.-1.28, p=0.006). Conclusion: The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.

KW - Breast cancer

KW - EGFR

KW - HER2

KW - Surgery

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=75149166478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149166478&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 5111

EP - 5119

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -